MorphoSys Xetra

MOR

DE0006632003

Market Closed - Xetra Other stock markets 11:36:08 2024-08-02 EDT			5-day change	1st Jan Change
67.25 ^EUR	-0.66%		-.--%	-.--%

MORPHOSYS : UBS reiterates its Neutral rating

Published on 2024-05-06 at 03:56, updated on 2024-05-06 at 04:43

UBS confirms his opinion on the stock and remains Neutral. The target price remains unchanged at EUR 68.

MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.

Employees

464

Sector

More about the company